The discovery that Tregs have a role in cancer has aided in the development of therapeutic antibodies to anti‐cytotoxic T lymphocyte associated antigen 4 (CTLA4) and anti‐programmed cell death protein 1 (PD1) as a novel and promising immunotherapeutic approach.23 If the role of Tregs can be elucidated in AD, then the use of such therapies targeting Treg function might provide a valuable and complementary approach to AD treatment. Here, CTLA4 is linked to Alzheimer disease.